Showing 821-830 of 5062 results for "".
- FDA Gives Nod to First Cell-Based Gene Therapy for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fda-gives-nod-to-first-cell-based-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa/2474382/The U.S. Food and Drug Administration (FDA) has approved ZEVASKYN (prademagene zamikeracel, pz-cel), making it the first cell-based gene therapy for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The approval addresses a major unmet clinical nee
- Novel TYK2 Inhibitor Shows Promising Results in Phase 2 Trials for PsOhttps://practicaldermatology.com/news/Novel-TYK2-Inhibitor-Shows-Promising-Results-Phase-2-Trials-PsO/2471545/The TYK2 inhibitor ESK-001 has shown promising safety and efficacy in long-term Phase 2 trials for moderate-to-severe plaque psoriasis, Andrew Blauvelt, MD, FAAD, said in a late-breaking research presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
- Analysis: AI Sensor Reduces Scratching in Atopic Dermatitis Patientshttps://practicaldermatology.com/news/ai-sensor-reduces-scratching-in-atopic-dermatitis/2471104/A wearable sensor utilizing artificial intelligence (AI) with haptic feedback significantly reduced nocturnal scratching in adults with mild atopic dermatitis, a new study reports. Researchers for the single-arm, two-stage cohort study recruited 10 adults (60% female; mean age, 36) with at
- FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-nemluvio-moderate-severe-atopic-dermatitis/2470663/Galderma’s Nemluvio® (nemolizumab) has received FDA approval for moderate-to-severe atopic dermatitis in patients aged 12 and older, offering a novel treatment option targeting IL-31. According to a press release from Galderma, the approval follows results from the phase III ARCADIA trial
- Report: Global Atopic Dermatitis Market Poised for Rapid Expansionhttps://practicaldermatology.com/news/report-global-atopic-dermatitis-market-poised-rapid-expansion/2468755/The atopic dermatitis (AD) market is forecasted to grow from $5.3 billion in 2021 to $22.6 billion by 2031, with a compound annual growth rate (CAGR) of 15.1%, according to a new report. North America as the current market leader, according to a press release from Allied Market Research,
- Analyses: Ruxolitinib Cream Reduces AD Symptom Burden in 12 Hourshttps://practicaldermatology.com/news/analyses-ruxolitinib-cream-reduces-ad-symptom-burden-12-hours/2468615/Ruxolitinib cream significantly reduced skin pain and improved patient-reported outcomes (PROs) in individuals with mild-to-moderate atopic dermatitis (AD), with improvements sustained over 52 weeks, according to data from the TRuE-AD1 and TRuE-AD2 studies. Researchers the results publishi
- Botanix Announces Expanded Payer Coverage for Sofdrahttps://practicaldermatology.com/news/botanix-announces-expanded-payer-coverage-sofdra/2468602/Botanix announced today that Ascent Health, second largest Payer (insurer) organization in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%, for the treatment of primary axillary hyperhydrosis. According to a press release from Botanix, Ascent represents approximat
- Study Backs CP-GEP Tests’ Accuracyhttps://practicaldermatology.com/news/study-backs-cp-gep-tests-accuracy/2468469/Patients with clinically node-negative primary cutaneous melanoma undergoing sentinel lymph node biopsies (SLNBs) who were classified as “high risk” according to CP-GEP tests were approximately three times more likely to be SLN positive, according to data presented October 13 at the Society of Me
- Study Links Psoriasis to NMSC in Womenhttps://practicaldermatology.com/news/study-links-psoriasis-nmsc-women/2468243/Psoriasis was associated with a higher risk of nonmelanoma skin cancer in women in a new study published in Nature Communications. “An observational and genetic investigation into the association between psoriasis and risk of malignancy” found higher risks of a total of 16 types of cancer
- Tralokinumab-ldrm 300 mg/2 mL Single-Dose Autoinjector Available in UShttps://practicaldermatology.com/news/tralokinumab-ldrm-300-mg2-ml-single-dose-autoinjector-available-us/2468195/The Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector is now available in the United States for patients 12 and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisab